Revvity, Inc. (RVTY)

Revvity's stock has experienced volatility over the past six months, with a 52-week range between $81.22 and $118.30. As of early May 2026, the stock price was around $86.51 to $101.00. On April 23, 2026, the stock saw a 7.6% drop due to investor focus on low organic growth and analyst caution. Revvity reported its Q1 CY2026 results on May 5, 2026, exceeding expectations but lowered its full-year guidance, leading to analyst pessimism and minor downgrades. Insider selling has also been noted.

Revvity experiences some demand seasonality, with a typical seasonal pickup in incremental revenue from Q1 to Q2. Overall demand is influenced by regulatory requirements, scientific advancements, and the need for reliable data generation. The company emphasizes recurring revenue through proprietary assays, reagents, software, and services to mitigate seasonal fluctuations.

Revvity, Inc. is a global life sciences and diagnostics company that emerged in 2023 after rebranding from PerkinElmer and is included in the S&P 500 index. It operates in the Healthcare sector, focusing on Diagnostics & Research and Advanced Medical Equipment & Technology industries, with segments in life sciences and diagnostics. The life sciences segment offers reagents, instruments, and software for biopharma and academic research, while the diagnostics segment provides tools for immunodiagnostics, newborn and reproductive health, and clinical diagnostics. Revvity's portfolio includes translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics, including its Signals software platform. Major products and services include reagents and consumables, laboratory instruments, workflow automation, software analytics, and technical support. Notable subsidiaries include BioLegend, EUROIMMUN, Tulip Diagnostics, and ViaCord.

Revvity's products and services are sold worldwide, with major markets in the United States, Europe, and China. The company maintains a global footprint with R&D, manufacturing, and customer support facilities across North America, Europe, Asia-Pacific, and Latin America. Key operational hubs in the U.S. include Waltham, Hopkinton, and San Diego. In Europe, significant locations include Cambridge, Codolet, and Turku. Beyond these regions, Revvity has active recruitment and operational hubs in Cracow, Shanghai, and Mumbai.

Revvity's brand reputation is shaped by its repositioning as a health-sciences company after rebranding from PerkinElmer in 2023. The company is recognized for enabling research continuity and diagnostic reliability. Analyst sentiment generally reflects a "Hold" consensus, with some "Buy" recommendations. Challenges include headwinds in the China market, macroeconomic conditions affecting industry funding, and supply chain disruptions, inflationary pressures, and labor shortages.

Institutional investors are the dominant owners of Revvity, holding approximately 95.01% to 101.70% of the company's stock. Insiders hold about 2.88%, while retail investors hold a negligible percentage. Major institutional shareholders include T. Rowe Price Investment Management Inc., Vanguard Group Inc., Price T Rowe Associates Inc /md/, EdgePoint Investment Group Inc., Janus Henderson Group Plc, BlackRock, Inc., State Street Corp, Geode Capital Management, Llc, Morgan Stanley, and Dimensional Fund Advisors Lp. T. Rowe Price Investment Management Inc. is the largest individual Revvity shareholder, owning 20.08% of the company.